TRAW
$2.17+0.06 (+2.87%)
Market OpenAs of Mar 17, 7:13 PM UTC
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2.17
Potential Upside
5%
Whystock Fair Value$2.28
Price
UndervaluedFair ValueOvervalued
Fundamentals
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are d...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$17.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.76
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-1059.63%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.07
Recent News
No recent news found.